Histone Deacetylase (HDAC) Inhibitors Market Report 2026

The histone deacetylase (hdac) inhibitors market size has grown strongly in recent years. It will grow from $1.32 billion in 2025 to $1.42 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing oncology drug research activity, rising understanding of epigenetic mechanisms, expansion of clinical trial programs, growing pharmaceutical r&d investments, availability of advanced molecular screening tools.

The histone deacetylase (hdac) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of personalized cancer therapies, rising investments in epigenetic drug development, expansion of neurology-related hdac research, growing demand for targeted therapeutics, increasing regulatory approvals for novel hdac inhibitors. Major trends in the forecast period include increasing focus on targeted epigenetic therapies, rising development of selective hdac inhibitors, growing use of combination oncology treatments, expansion of precision medicine drug pipelines, enhanced emphasis on biomarker-driven drug discovery.

The rising incidence of neurodegenerative disorders is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market in the coming years. Neurodegenerative disorders, marked by the progressive degeneration and death of neurons in the brain and spinal cord, result in cognitive and motor impairments and include conditions such as Alzheimer's disease, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. The increasing prevalence of these disorders can be attributed to factors such as aging, longer life expectancy, genetic predisposition, and environmental influences. HDAC inhibitors are being investigated as potential treatments for neurodegenerative disorders due to their capacity to modulate gene expression and offer neuroprotective benefits. For example, in August 2024, the Centers for Disease Control and Prevention reported that approximately 6.7 million older adults in the United States are living with Alzheimer's disease, a figure projected to rise to nearly 14 million by 2060. Consequently, the growing incidence of neurodegenerative disorders is fueling the expansion of the HDAC inhibitors market.

Key players in the HDAC inhibitors market are concentrating on developing innovative solutions, such as HDAC inhibitors for cancer therapy, to enhance treatment efficacy while reducing adverse effects. HDAC inhibitors are a class of pharmaceutical compounds used in oncology that inhibit the activity of HDAC enzymes, which typically remove acetyl groups from histone proteins. This inhibition increases histone acetylation, altering chromatin structure and modulating gene expression. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based developer of first-in-class cancer therapies, was granted new HDAC inhibitor patents for cancer treatment by the U.S. Patent and Trademark Office. These novel inhibitors are designed to target specific HDAC enzymes involved in cancer progression, aiming to disrupt abnormal gene expression patterns that drive tumor growth and metastasis. The patented compounds show improved potency and selectivity, minimizing off-target effects and enhancing safety for patients undergoing therapy.

In June 2024, Italfarmaco SpA, a US-based pharmaceutical company, entered into a partnership with Iktos SA for an undisclosed sum. Through this collaboration, they plan to accelerate drug discovery in non-oncological areas by using AI to design advanced HDAC inhibitors. Iktos SA, a France-based technology company, specializes in artificial intelligence solutions for medicinal chemistry and drug development.

Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the histone deacetylase (hdac) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the histone deacetylase inhibitors market by increasing costs of imported active pharmaceutical ingredients, specialized reagents, laboratory equipment, and drug development technologies. Pharmaceutical companies and research institutes in North America and Europe are most affected due to dependence on global chemical supply chains, while Asia-Pacific faces cost pressures on manufacturing and export of drug compounds. These tariffs are raising development expenses and extending trial timelines. However, they are also encouraging domestic API production, regional contract manufacturing expansion, and localized drug development capabilities.

The histone deacetylase (hdac) inhibitors market research report is one of a series of new reports that provides histone deacetylase (hdac) inhibitors market statistics, including histone deacetylase (hdac) inhibitors industry global market size, regional shares, competitors with a histone deacetylase (hdac) inhibitors market share, detailed histone deacetylase (hdac) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase (hdac) inhibitors industry. This histone deacetylase (hdac) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Histone deacetylase (HDAC) inhibitors are a class of compounds that inhibit the activity of histone deacetylase enzymes. These enzymes remove acetyl groups from histone proteins, resulting in a more condensed chromatin structure and reduced gene expression. By inhibiting these enzymes, HDAC inhibitors promote hyperacetylation of histones, which generally relaxes chromatin structure and increases DNA accessibility for transcription factors.

The primary classes of HDAC inhibitors include class I, class II, class III, and class IV HDACs. Class I HDACs mainly regulate gene expression by modifying chromatin structure and are involved in multiple cellular processes. They have been extensively studied for their potential therapeutic applications in cancer and other diseases. HDAC inhibitors can be administered via various routes, including oral and parenteral methods. Their applications span oncology, neurology, and other therapeutic areas, and they are utilized by end users such as hospitals, academic and research institutions, pharmaceutical companies, and others.

The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.